Aqua Bio Technology ASA: Acquisition of the 3D Innovation Nordic AS group completed

Reference is made to the stock exchange announcement made by Aqua Bio Technology ("ABT" or the "Company", and together with its wholly owned subsidiaries, the "ABT Group") on 25 April 2024 regarding the Company's entry to an agreement in principle to acquire all of the outstanding shares in 3D Innovation Nordic AS ("3D Innovation") (the "Transaction"). 3D Innovation with its subsidiaries represent a major wholesale group in the Nordics (the "Target Group").

The Transaction has today been completed making ABT the 100 % direct and indirect owner of the Target Group. 

For the first half of 2024, the Target Group had an unaudited turnover of NOK 40 million with an EBITDA of NOK 3 million.  

The purchase price for the Transaction shall be settled in a combination of shares and cash, subject to certain conditions. The share component comprises of ABT issuing 5,000,000 new shares at subscription price of NOK 3,66 per share, equal to today's opening trading price of the Company's shares, with a 3-year lock up (the "Consideration Shares"). The cash component will in total be NOK 15 million, divided into two installments, depending on the Target Group's financial results. The first NOK 5 million is triggered by an EBT of NOK 6 million in the Target Group, the next NOK 10 million when the Target Group achieves an EBT of NOK 10 million.

The Company's board of directors will convene at a later date to formally issue the Consideration Shares.

3D Innovation Nordic AS ("3D Innovation"), which has its head office and sales department in Hønefoss, has extensive distribution to all the major retail chains in Norway and pharmacies in Norway and Sweden, as well as selected customers in Denmark. The company has had considerable success in just a few years and is at the top of the Gazelle award for 2022. As such, the Transaction positions ABT for new and unique distribution channels enabling ABT to become a more comprehensive supplier in the retails and sales area to the cosmetic markets in the Nordics. It is well known in this segment that these distribution channels are both difficult to gain access to and are of strategic importance. In interaction with ABT's historical operations and the operations of the ABT Group, the Transaction is therefore expected to provide significant synergies on several levels.

 

****

For further information, please contact CEO Håvard Lindstrøm mobile phone +47 941 32 288.

Aqua Bio Technology (ABT) is developing and commercializing sustainable biotechnology for use in skincare products. ABT's cosmetics ingredients are highly effective and they provide the cosmetics industry with natural alternatives to traditional ingredients. ABT is also marketing and distributing natural skincare products developed by partners towards consumers and professional users. ABT's focus on commercialization and development of natural ingredients and natural skincare products has been, and will continue to be, an important part of the Company's strategy going forward. Aqua Bio Technology is listed on the Euronext Expand market of the Oslo Stock Exchange.

This information is considered to be inside information pursuant to the EU Market Abuse Regulation and subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. This stock exchange notice was published by CEO Håvard Lindstrøm on the date and time provided.